158 related articles for article (PubMed ID: 36939611)
1. Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments.
Köksal AŞ; Toka B; Sadeçolak M; Acar Ş; Eminler AT; Tozlu M; Karabay O
Turk J Gastroenterol; 2023 May; 34(5):552-559. PubMed ID: 36939611
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy.
Köksal AS; Toka B; Eminler AT; Hacıbekiroğlu I; Sunu C; Uslan MI; Karabay O; Parlak E
Acta Gastroenterol Belg; 2019; 82(2):279-284. PubMed ID: 31314189
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
[TBL] [Abstract][Full Text] [Related]
4. Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy.
Asai A; Hirai S; Yokohama K; Nishikawa T; Nishikawa H; Higuchi K
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566572
[TBL] [Abstract][Full Text] [Related]
5. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
Yenilmez E; Cetinkaya RA
Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
[TBL] [Abstract][Full Text] [Related]
9. Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.
Toka B; Eminler AT; Gönüllü E; Tozlu M; Uslan MI; Parlak E; Karabay O; Koksal AS
Rheumatol Int; 2019 Dec; 39(12):2077-2085. PubMed ID: 31520109
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.
Laiwatthanapaisan R; Sripongpun P; Chamroonkul N; Dechaphunkul A; Sathitruangsak C; Sakdejayont S; Kongkamol C; Piratvisuth T
Clin Mol Hepatol; 2019 Dec; 25(4):366-373. PubMed ID: 31309773
[TBL] [Abstract][Full Text] [Related]
11. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
[TBL] [Abstract][Full Text] [Related]
16. Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.
Brakenhoff SM; Hoekstra R; Honkoop P; Roomer R; den Hollander JG; Bezemer G; de Knegt RJ; Sonneveld MJ; de Man RA
Eur J Intern Med; 2023 Feb; 108():68-73. PubMed ID: 36462966
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion.
Papatheodoridis GV; Lekakis V; Voulgaris T; Lampertico P; Berg T; Chan HLY; Kao JH; Terrault N; Lok AS; Reddy KR
J Hepatol; 2022 Dec; 77(6):1670-1689. PubMed ID: 35850281
[TBL] [Abstract][Full Text] [Related]
18. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus.
Chen MH; Wu CS; Chen MH; Tsai CY; Lee FY; Huang YH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502025
[TBL] [Abstract][Full Text] [Related]
19. Universal hepatitis B screening and management in patients with cancer who received immunosuppressive chemotherapy.
Thompson LA; Heath LJ; Freml H; Delate T
J Oncol Pharm Pract; 2020 Jul; 26(5):1141-1146. PubMed ID: 31789111
[TBL] [Abstract][Full Text] [Related]
20. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
